These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 1830273

  • 1. Initial experience with SPECT examinations using [123I]IBZM as a D2-dopamine receptor antagonist in Parkinson's disease.
    Cordes M, Henkes H, Laudahn D, Bräu H, Kramp W, Girke W, Hierholzer J, Eichstädt H, Felix R.
    Eur J Radiol; 1991; 12(3):182-6. PubMed ID: 1830273
    [Abstract] [Full Text] [Related]

  • 2. [Dopamine (D2) receptor SPECT with 123I-iodobenzamide (IBZM) in diagnosis of Parkinson syndrome].
    Reiche W, Grundmann M, Huber G.
    Radiologe; 1995 Nov; 35(11):838-43. PubMed ID: 8657887
    [Abstract] [Full Text] [Related]

  • 3. SPECT imaging of dopamine D2 receptors with 123I-IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease.
    Tatsch K, Schwarz J, Oertel WH, Kirsch CM.
    Nucl Med Commun; 1991 Aug; 12(8):699-707. PubMed ID: 1838142
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of [123I]IBZM pinhole SPECT for the detection of striatal dopamine D2 receptor availability in rats.
    Scherfler C, Scholz SW, Donnemiller E, Decristoforo C, Oberladstätter M, Stefanova N, Diederen E, Virgolini I, Poewe W, Wenning GK.
    Neuroimage; 2005 Feb 01; 24(3):822-31. PubMed ID: 15652317
    [Abstract] [Full Text] [Related]

  • 5. Diagnostic value of asymmetric striatal D2 receptor upregulation in Parkinson's disease: an [123I]IBZM and [123I]FP-CIT SPECT study.
    Verstappen CC, Bloem BR, Haaxma CA, Oyen WJ, Horstink MW.
    Eur J Nucl Med Mol Imaging; 2007 Apr 01; 34(4):502-7. PubMed ID: 17053905
    [Abstract] [Full Text] [Related]

  • 6. [The determination of cerebral dopamine (D2) receptor density by using 123I-IBZM-SPECT in Parkinson disease patients].
    Hierholzer J, Cordes M, Schelosky L, Barzen G, Poewe W, Henkes H, Keske U, Horowski R, Felix R.
    Rofo; 1992 Oct 01; 157(4):390-8. PubMed ID: 1391843
    [Abstract] [Full Text] [Related]

  • 7. Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes.
    Hierholzer J, Cordes M, Venz S, Schelosky L, Harisch C, Richter W, Keske U, Hosten N, Mäurer J, Poewe W, Felix R.
    J Nucl Med; 1998 Jun 01; 39(6):954-60. PubMed ID: 9627325
    [Abstract] [Full Text] [Related]

  • 8. Correlation of clinical response in apomorphine test with D2-receptor status as demonstrated by 123I IBZM-SPECT.
    Schelosky L, Hierholzer J, Wissel J, Cordes M, Poewe W.
    Mov Disord; 1993 Oct 01; 8(4):453-8. PubMed ID: 8232354
    [Abstract] [Full Text] [Related]

  • 9. [123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy.
    Schwarz J, Tatsch K, Gasser T, Arnold G, Oertel WH.
    Mov Disord; 1997 Nov 01; 12(6):898-902. PubMed ID: 9399212
    [Abstract] [Full Text] [Related]

  • 10. Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796.
    Seibyl JP, Zea-Ponce Y, Brenner L, Baldwin RM, Krystal JH, Offord SJ, Mochoviak S, Charney DS, Hoffer PB, Innis RB.
    J Nucl Med; 1996 Jan 01; 37(1):11-5. PubMed ID: 8543979
    [Abstract] [Full Text] [Related]

  • 11. In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by [123I]IBZM and single photon emission computed tomography.
    Videbaek C, Toska K, Friberg L, Holm S, Angelo HR, Knudsen GM.
    J Cereb Blood Flow Metab; 2001 Jan 01; 21(1):92-7. PubMed ID: 11149673
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [The differential diagnosis of Parkinson diseases--123I-IBZM-SPECT vs. the apomorphine test].
    Hierholzer J, Cordes M, Schelosky L, Sander B, Böck JC, David I, Horowski R, Poewe W.
    Rofo; 1993 Jul 01; 159(1):86-90. PubMed ID: 8334264
    [Abstract] [Full Text] [Related]

  • 20. In vitro and in vivo D2-dopamine receptor binding with [123I]S(-) iodobenzamide ([123I]IBZM) in rat and human brain.
    Verhoeff NP, Bobeldijk M, Feenstra MG, Boer GJ, Maas MA, Erdtsieck-Ernste E, de Bruin K, van Royen EA.
    Int J Rad Appl Instrum B; 1991 Jul 01; 18(8):837-46. PubMed ID: 1839302
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.